Dublin, July 30, 2018 (GLOBE NEWSWIRE) -- The "Organ-On-A-Chip Innovations Fueling Drug Screening Applications" report has been added to ResearchAndMarkets.com's offering.
Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight into the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human-relevant per se but can mimic a wide variety of human functions such as breathing, heartbeats, peristalsis, menstruation, neuronal communication. Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human-relevant systems. The US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom, and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.
Key Topics Covered:
1. Executive Summary 1.1 Research Scope - Application of Organ-on-a-chip Technology in Drug Screening Process 1.2 Research Methodology - Core Value 1.3 Key Findings: Organ-on-a-chip Technology 2. Technology Snapshot 2.1 A Brief Overview of Organ-on-a-chip Functioning 2.2 Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes 2.3 Current Trends in the Organ-on-a-chip platform 3. Organ-on-a-chip Platforms 3.1 Heart-on-a-chip Platform 3.2 Liver-on-a-chip Platform 3.2.1 High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications 3.2.2 Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability 3.3 Lung-on-a-chip Platform 3.3.1 Lung-on-a-chip: Platform Overview, Application, Disadvantages, and Features 3.4 Kidney-on-a-chip Platform 3.4.1 Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges 3.5 Gut-on-a-chip/Intestine-on-a-chip Platform 3.5.1 Intestine- and Gut-on-a-chip Serve as Enhanced Study Models 3.5.2 Intestine- and Gut-on-a-chip: The Applications and the Challenges 3.6 Nerve-on-a-chip Platform 3.6.1 Evaluation of Neurotoxicity with the Nerve-on-a-chip platform 3.7 Muscle-on-a-chip Platform 3.7.1 Muscle-on-Chip Platform to Determine Long-term rug effects on Muscle Loss and Toxicity 3.7.2 Muscle-on-a-chipPhysiology, Features and Application Areas 3.8 Brain-on-a-chip Platform 3.8.1 Emulation of Human-Blood-Brain Barrier 3.9 Multi-Organ Chip Platforms 3.10 Human-on-a-chip Platform 4. Drivers and Challenges of Organ-Chip Technology 4.1 Drivers and Challenges Impact Chart of Organ-Chip Technology 4.2 Organ-on-a-chip Technology 4.3 Stem ell henotypes key to unlocking vast otential of Organ-chip Systems 5. Major Organ-on-a-chip Companies 5.1 A Well-defined and Robust Nerve-on-a-chip Platform 5.2 CN Bio- UK's Organ-chip Technology Pioneer 5.3 Emulate propelling Drug Screening and Development through their 5.4 Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems 5.5 Liver-on-a-chip platforms with High Biological Fidelity 5.6 Scaffold-free Human Relevant Liver-on-a-Chip Systems 5.7 Validated Research-ready Organ-chip Systems 5.8 Organ-Chips that facilitate High Throughput Screening 5.9 Precise Flow-controlled ParVivo Organ-Chip Systems 5.10 Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform 5.11 TissUse pioneering Human-on-a-Chip platform 6. Intellectual Property Landscape of Organ-on-a-chip Technology 6.1. Patent Research Scope and Concepts 6.2 Top 20 Patent Holders in the Organ-on-a-chip Platform 6.3 Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008-2018* 6.4 Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008-2017 7. Funding Landscape of Organ-on-a-chip Technology 7.1 Funding Strength of Organ-Chip Technology- Global View 7.2 Government Funding for Organ-on-a-chip Development 7.3 Venture Capitalist-based Investment Funding in the OOC Market 7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development 8. Growth Opportunities 8.1 Growth Opportunity 1: Personalized Medicine 8.2 Growth Opportunity 2: Animal Model Replacement 8.3 Growth Opportunity 3: Identification of Biomarkers 8.4 Determinants of Organ-on-a-chip Platform's Impact on Drug Screening Process 9. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/z...nchip?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Drug Abuse Screening, Biomaterials
